CA Patent

CA2900763C — Pharmaceutical compositions for the treatment of helicobacter pylori

Assigned to Redhill Biopharma Ltd · Expires 2021-04-06 · 5y expired

What this patent protects

Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some asp…

USPTO Abstract

Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.

Drugs covered by this patent

Patent Metadata

Patent number
CA2900763C
Jurisdiction
CA
Classification
—
Expires
2021-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Redhill Biopharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.